Pulse Check
  • News
    • Startup Funding & Exits
    • AI-Native Startups
    • Women’s & Family Health
    • Metabolic & Mental Health
    • Preventative Health & Diagnostics
    • Virtual Specialty Care
  • Spotlight
    • Branding Spotlight
    • Content Spotlight
  • Startup Watch
    • Featured Startup Spotlight
    • Startups to Watch
Select Page
The biotech IPO window is reopening, but “Rule of 40” is the new admission price

The biotech IPO window is reopening, but “Rule of 40” is the new admission price

by admin@pulsecheck.news | Aug 8, 2026 | Startup Funding & Exits

Other Articles

  • Joon: A game kids actually want to play turns daily tasks into treatment
  • Access used to be enough for a women’s health startup. Now investors want proof it worked.
  • The biotech IPO window is reopening, but “Rule of 40” is the new admission price
  • Behavioral health claims are 36 times any other telehealth category, and that concentration made and unmade startups this year
  • Preventive health screening raised big checks in 2026, but the money went to six companies
©2026. All rights reserved.